Injectable Anti-diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Injectable Anti-Diabetic Drugs Market Report is Segmented Into Insulin (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Glucagon-Like Peptide-1 (GLP-1) Agonist Drugs (dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Injectable Anti-diabetic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Injectable Anti-diabetic Drugs Industry Overview

The injectable anti-diabetic drugs market is consolidated, with major manufacturers, namely Eli Lilly, Novo Nordisk, and Sanofi, among others, holding a presence in all regions. Mergers and acquisitions that have happened between the players in the recent past helped the companies strengthen their market presence. For instance, Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).

Injectable Anti-diabetic Drugs Market Leaders

  1. Novo Nordisk

  2. Lilly

  3. Julphar

  4. Biocon

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
Injectable Anti-diabetic Drugs Market Concentration

Injectable Anti-diabetic Drugs Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?